Synapsoft logo
AI Insights from Disclosures
Searching...
CJ Bioscience 311690
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
CJ Bioscience declared its '2024 New Vision' statement, under which it has adopted the vision of becoming 'A Global Innovator in Healthcare through AI-powered Microbiome Science' with competitiveness in the global market by consolidating AI-based R&D technology and capabilities. In its (1) microbiome therapeutics (new drug development) business, CJRB-101, a new drug candidate independently discovered and isolated from fermented food, has shown preclinical data demonstrating a tumor growth-inhibiting effect against lung cancer, and has received IND approval for Phase 1/2 clinical trials from the US FDA (January 20, 2023) and from Korea's MFDS, the Ministry of Food and Drug Safety (June 15, 2023); clinical trials are ongoing in the United States and Korea, with the first patient dosed in Korea in October 2023.
Representative Director Yoon Sangbae
Founded November 18, 2009
Corporation Type KOSDAQ
Industry Classification Research and experimental development on natural sciences and engineering
Corporate number 11011-4222503
Business number 119-86-23145
Phone Number 02-6078-3456
Fax Number 02-6078-3457
Company Address 14 Sejong-daero, Jung-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant